Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs acetylsalicylic acid for thromboprophylaxis in children after Fontan procedure
2015-002610-76Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of rivaroxaban in venous thromboembolism (VTE), Single Ventricle Heart Defects and cardiac morbidity (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Pharmacokinetics of rivaroxaban, Pharmacodynamics of rivaroxaban and 2 more. Started Jul 2016; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)Single Ventricle Heart Defectscardiac morbidity
Beyond the preview
Go deeper on 2015-002610-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002610-76.